Publications

A range of publications and thought leadership is available to UK pharmaceuticals companies:

Pharma 2020: Taxing times ahead
The fifth in the Pharma 2020 series focuses on the opportunities and challenges facing the pharmaceuticals and life sciences industry from a tax perspective. It discusses how the political, economic, scientific and social trends currently shaping the commercial environment, together with the development of new, more collaborative business models, will exert increasing pressure on effective tax rates within the industry. It also shows how companies can adapt their tax strategies to support the provision of outcomes-based healthcare and remain competitive.

Pharma 2020: Challenging business models
The fourth in the Pharma 2020 series, explains how even the largest pharmaceutical companies will have to collaborate more closely with players inside and outside the sector to be able to respond to the demands from the different stakeholder communities.

Investing in China's Pharmaceutical Industry
Second edition of a paper looking into the current pharmaceutical market conditions in China, the report covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors.

Pharma 2020: Marketing the future - which path will you take?
The third in the Pharma 2020 series, outlines a confluence of dynamics that lead to a new marketing and sales system with a smaller, more agile and smarter sales force.

Pharma 2020: The vision - which path will you take?
This podcast and global report looks at the challenges facing the pharmaceuticals sector in the lead up to 2020.

IFRS - impact on financial reporting for the life sciences sector

BioForum - latest issue
This edition reports market performance data for another strong quarter and a milestone of $30 billion total market value for the Biotechnology sector. The market has shown consistent strength in the capital raising through initial public offerings and secondary raisings in both the biotech/pharma and medical device subsectors.

Unlocking the power of pharmacovigilance
This report is a focused analysis of the current state of drug safety monitoring (known as pharmacovigilance) and a guide to field-tested operational strategies that can be employed to improve current pharmacovigilance practices.

Restoring trust in the pharmaceutical industry by translating expectations into actions
This report provides an in-depth analysis of one of the most pressing issues facing the global pharmaceutical industry today – its reputation and how it deals with perceptions about its business and operational models.

International Financial Reporting Standards (IFRS): Issues and solutions for the pharma industry
A series of in-depth publications designed to create dialogue and debate around the issues of implementing IFRS and encourage consistent global best practices in financial reporting under these new standards.

A better shape for the future: Building value through integration and partnerships
This European pharmaceutical market survey from PricewaterhouseCoopers & Siemens demonstrates that there is a demand for truly integrated multi-disciplinary services.

Pharmaceutical Insights: Analysis and Opinions on Merger & Acquisition Activity
An annual overview of M&A activity in the global pharmaceuticals industry, together with analysis of the principal trends and driving forces in the arena, now and in the future.

Prescription for Growth – series of papers
A series of paper examining the opportunities and risks attached to investing in developing markets. The series includes focuses on China, India and Latin America.